Research Chemical Designation & Liability

Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.

Full Disclaimer
Archive Identifier

Amycretin

Metabolic & Weight Loss

Molecular Dossier

  • Rank Index: 47
  • Status: Phase 2 Clinical
  • What does this mean?
  • Molecular Structure: GLP-1/Amylin Receptor Co-Agonist

About Amycretin

Novo Nordisk's investigational unimolecular GLP-1/Amylin receptor co-agonist. Phase 2 data demonstrated up to 22% body weight reduction at 36 weeks, making it one of the most potent anti-obesity compounds in clinical development.

Clinical Focus

GLP-1/Amylin Dual Agonism & Weight Reduction

Archival Aliases

AM-833, GLP-1/Amylin Combo

Frequently Asked Questions

Clinical Data Matrix

Parameter Clinical Value
Molecular Weight GLP-1/Amylin Receptor Co-Agonist
Primary Pathway Metabolic & Weight Loss
Research Phase Phase 2 Clinical

Clinical Pros

  • Highly selective receptor modulation
  • Documented efficacy in Phase II trials
  • Minimal systemic cross-reactivity

Research Limitations

  • Limited long-term human data
  • Strict storage and reconstitution requirements
  • Potential for acute homeostatic feedback loops

Community Discussion

Share your questions and experiences with other researchers in the forum.

Discuss in Forum

Clinical Reference Nodes

[REF 1] nejm.org
[REF 2] clinicaltrials.gov

Data Verified: 2026-04-10

Synergistic Matrix